What are the brand names for Inhaled Corticosteroids (ICS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brand Names for Inhaled Corticosteroids (ICS)

The main brand names for inhaled corticosteroids (ICS) include Flovent/Flixotide (fluticasone propionate), Pulmicort (budesonide), Qvar (beclomethasone dipropionate), Asmanex (mometasone), Alvesco (ciclesonide), Aerospan (flunisolide), and Azmacort (triamcinolone). 1

Available ICS Medications and Their Brand Names

Inhaled corticosteroids are the cornerstone of asthma management for persistent asthma due to their potent anti-inflammatory effects. They reduce airway hyperresponsiveness, inhibit inflammatory cell migration and activation, and block late-phase reactions to allergens 1. The following are the major ICS medications available:

Single-Agent ICS Products

  • Fluticasone propionate

    • Brand names: Flovent (US), Flixotide (Europe) 2
    • Available in MDI and dry powder devices (Diskus)
    • Dosages range from 44-500 mcg/puff
  • Budesonide

    • Brand name: Pulmicort Turbuhaler/Flexhaler
    • Available in dry powder inhaler and nebulizer solution
  • Beclomethasone dipropionate

    • Brand names: Qvar, Beclovent
    • Available in HFA-propelled MDI formulation 1
  • Mometasone furoate

    • Brand name: Asmanex
    • Available in dry powder inhaler 1
  • Ciclesonide

    • Brand name: Alvesco
    • Available in HFA-propelled MDI 1
  • Flunisolide

    • Brand name: Aerospan (formerly Aerobid)
    • Available in HFA-propelled MDI 1
  • Triamcinolone acetonide

    • Brand name: Azmacort
    • Available in MDI 1

Combination ICS/LABA Products

ICS are also available in fixed-dose combinations with long-acting beta-agonists (LABAs):

  • Fluticasone propionate/Salmeterol

    • Brand names: Advair (US), Seretide (Europe), Adoair (Japan) 3
  • Budesonide/Formoterol

    • Brand name: Symbicort 3
    • Also approved in some countries as maintenance and reliever therapy (Symbicort SMART)
  • Beclomethasone/Formoterol

    • Brand name: Foster 3

Relative Potency of Different ICS Products

When switching between different ICS products, it's important to consider their relative potencies:

  • Fluticasone propionate is approximately twice as potent as beclomethasone dipropionate, budesonide, or triamcinolone acetonide 2
  • The potency ratio between Flixotide Diskus (fluticasone propionate) and Pulmicort Turbuhaler (budesonide) is approximately 1.5:1 to 1.75:1 4

Delivery Devices

ICS are delivered through various devices that may affect drug delivery and clinical efficacy:

  • Metered Dose Inhalers (MDIs): Most ICS are available in MDI format, many now using HFA propellants
  • Dry Powder Inhalers (DPIs): Including Diskus/Accuhaler, Turbuhaler/Flexhaler
  • Nebulizers: Particularly useful for young children, elderly patients, or those with coordination difficulties 5

Clinical Considerations

When prescribing ICS, several factors should be considered:

  • For patients with persistent asthma, ICS are the most consistently effective long-term control medication at all steps of care 1
  • ICS improve asthma control more effectively than leukotriene receptor antagonists or any other single long-term control medication 1
  • Combination therapy with ICS and LABA in a single inhaler may provide better asthma control than administering the drugs in separate inhalers 6

Pitfalls and Caveats

  • LABAs should never be used as monotherapy for asthma control; they must always be prescribed with an ICS 1
  • Different ICS products and delivery devices have varying lung deposition characteristics, which can affect clinical efficacy 5
  • When switching between different ICS products, dose adjustments may be necessary due to differences in potency 4
  • High-dose ICS therapy may be associated with systemic effects, including potential adrenal suppression 1

By understanding the available ICS products and their brand names, clinicians can make informed decisions when prescribing these essential medications for asthma management.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.